Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet. 2006 Mar 4;367(9512):754-65.

Testicular germ-cell cancer.

Author information

  • 1Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK. alan.horwich@icr.ac.uk

Erratum in

  • Lancet. 2006 Apr 29;367(9520):1398.

Abstract

Testicular germ-cell tumours (TGCTs) represent the model of a curable malignancy; sensitive tumour markers, accurate prognostic classification, logical series of management trials, and high cure rates in both seminomas and non-seminomas have enabled a framework of effective cancer therapy. Understanding the molecular biology of TGCT could help improve treatment of other cancers. The typical presentation in young adults means that issues of long-term toxicity become especially important in judging appropriate management. A focus of recent developments has been to tailor aggressiveness of treatment to the severity of the prognosis. Recent changes affect the most common subtypes and include the reduction of chemotherapy for patients who have metastastic non-seminomas and a good prognosis, and alternatives to adjuvant radiotherapy in stage I seminomas. We summarise advances in the understanding and management of TGCT during the past decade.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk